Arabic Arabic English English French French German German
dark

 Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, announced dosing of the first patient in the United States with LYS-GM101 investigational gene therapy at CHOC Hospital in a global adaptative-design clinical trial for the treatment of GM1 gangliosidosis. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

XPhyto Launches First Commercial Biosensor for Oral Disease

Next Post

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Related Posts
Total
0
Share